{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:22:55Z","timestamp":1790752975824,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:00:00Z","timestamp":1539043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:00:00Z","timestamp":1539043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH intramural grant to Dr. Electron Kebebew"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adrenocortical cancer (ACC) is a rare cancer with poor prognosis and high mortality due to metastatic disease. All reported genetic alterations have been in primary ACC, and it is unknown if there is molecular heterogeneity in ACC. Here, we report the genetic changes associated with metastatic ACC compared to primary ACCs and tumor heterogeneity. We performed whole-exome sequencing of 33 metastatic tumors. The overall mutation rate (per megabase) in metastatic tumors was 2.8-fold higher than primary ACC tumor samples. We found tumor heterogeneity among different metastatic sites in ACC and discovered recurrent mutations in several novel genes. We observed 37\u201357% overlap in genes that are mutated among different metastatic sites within the same patient. We also identified new therapeutic targets in recurrent and metastatic ACC not previously described in primary ACCs.<\/jats:p>","DOI":"10.1038\/s41467-018-06366-z","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T10:55:15Z","timestamp":1538564115000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors"],"prefix":"10.1038","volume":"9","author":[{"given":"Sudheer Kumar","family":"Gara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Lack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerson","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Cam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Electron","family":"Kebebew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,9]]},"reference":[{"key":"6366_CR1","doi-asserted-by":"publisher","first-page":"6304","DOI":"10.1523\/JNEUROSCI.0961-08.2008","volume":"28","author":"CP Billimoria","year":"2008","unstructured":"Billimoria, C. P., Kraus, B. J., Narayan, R., Maddox, R. K. & Sen, K. Invariance and sensitivity to intensity in neural discrimination of natural sounds. J. Neurosci. 28, 6304\u20136308 (2008).","journal-title":"J. Neurosci."},{"key":"6366_CR2","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1210\/er.2013-1029","volume":"35","author":"T Else","year":"2014","unstructured":"Else, T. et al. Adrenocortical carcinoma. Endocr. Rev. 35, 282\u2013326 (2014).","journal-title":"Endocr. Rev."},{"key":"6366_CR3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0002-9440(10)63846-1","volume":"162","author":"TJ Giordano","year":"2003","unstructured":"Giordano, T. J. et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am. J. Pathol. 162, 521\u2013531 (2003).","journal-title":"Am. J. Pathol."},{"key":"6366_CR4","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/ng.2953","volume":"46","author":"G Assie","year":"2014","unstructured":"Assie, G. et al. Integrated genomic characterization of adrenocortical carcinoma. Nat. Genet. 46, 607\u2013612 (2014).","journal-title":"Nat. Genet."},{"key":"6366_CR5","doi-asserted-by":"publisher","first-page":"7622","DOI":"10.1158\/0008-5472.CAN-05-0593","volume":"65","author":"F Tissier","year":"2005","unstructured":"Tissier, F. et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 65, 7622\u20137627 (2005).","journal-title":"Cancer Res."},{"key":"6366_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7302","volume":"6","author":"EM Pinto","year":"2015","unstructured":"Pinto, E. M. et al. Genomic landscape of paediatric adrenocortical tumours. Nat. Commun. 6, 6302 (2015).","journal-title":"Nat. Commun."},{"key":"6366_CR7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ccell.2016.07.013","volume":"30","author":"S Zheng","year":"2016","unstructured":"Zheng, S. et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell.\u00a029, 723\u2013736 (2016); erratum\u00a030, 363 (2016).","journal-title":"Cancer Cell."},{"key":"6366_CR8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1677\/erc.1.01029","volume":"12","author":"DE Schteingart","year":"2005","unstructured":"Schteingart, D. E. et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr. Relat. Cancer 12, 667\u2013680 (2005).","journal-title":"Endocr. Relat. Cancer"},{"key":"6366_CR9","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/cncr.24030","volume":"115","author":"M Fassnacht","year":"2009","unstructured":"Fassnacht, M. et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 115, 243\u2013250 (2009).","journal-title":"Cancer"},{"key":"6366_CR10","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","volume":"16","author":"M Fassnacht","year":"2015","unstructured":"Fassnacht, M. et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 16, 426\u2013435 (2015).","journal-title":"Lancet Oncol."},{"key":"6366_CR11","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/bjc.2013.46","volume":"108","author":"A Naing","year":"2013","unstructured":"Naing, A. et al. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br. J. Cancer 108, 826\u2013830 (2013).","journal-title":"Br. J. Cancer"},{"key":"6366_CR12","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1210\/jc.2013-2298","volume":"99","author":"C O\u2019Sullivan","year":"2014","unstructured":"O\u2019Sullivan, C. et al. The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. J. Clin. Endocrinol. Metab. 99, 1291\u20131297 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"6366_CR13","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214\u2013218 (2013).","journal-title":"Nature"},{"key":"6366_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nature05610","volume":"446","author":"C Greenman","year":"2007","unstructured":"Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153\u2013158 (2007).","journal-title":"Nature"},{"key":"6366_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mrfmmm.2013.04.009","volume":"743-744","author":"K Williams","year":"2013","unstructured":"Williams, K. & Sobol, R. W. Mutation research\/fundamental and molecular mechanisms of mutagenesis: special issue: DNA repair and genetic instability. Mutat. Res. 743-744, 1\u20133 (2013).","journal-title":"Mutat. Res."},{"key":"6366_CR16","first-page":"1961","volume":"60","author":"CX Liu","year":"2000","unstructured":"Liu, C. X. et al. LRP-DIT, a putative endocytic receptor gene, is frequently inactivated in non-small cell lung cancer cell lines. Cancer Res. 60, 1961\u20131967 (2000).","journal-title":"Cancer Res."},{"key":"6366_CR17","doi-asserted-by":"publisher","first-page":"9327","DOI":"10.1093\/nar\/gkv908","volume":"43","author":"SK Gara","year":"2015","unstructured":"Gara, S. K. et al. Integrated genome-wide analysis of genomic changes and gene regulation in human adrenocortical tissue samples. Nucl. Acids Res. 43, 9327\u20139339 (2015).","journal-title":"Nucl. Acids Res."},{"key":"6366_CR18","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1210\/jc.2002-021117","volume":"88","author":"MH Bernard","year":"2003","unstructured":"Bernard, M. H. et al. A case report in favor of a multistep adrenocortical tumorigenesis. J. Clin. Endocrinol. Metab. 88, 998\u20131001 (2003).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"6366_CR19","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1001\/jamaoncol.2015.1313","volume":"1","author":"H Beltran","year":"2015","unstructured":"Beltran, H. et al. Whole-exome sequencing of metastatic cancer and biomarkers of treatment response. JAMA Oncol. 1, 466\u2013474 (2015).","journal-title":"JAMA Oncol."},{"key":"6366_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-146","volume":"13","author":"J Zhang","year":"2013","unstructured":"Zhang, J. et al. Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient. BMC Cancer 13, 146 (2013).","journal-title":"BMC Cancer"},{"key":"6366_CR21","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.ejca.2015.02.012","volume":"51","author":"S Vignot","year":"2015","unstructured":"Vignot, S. et al. Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles. Eur. J. Cancer 51, 791\u2013799 (2015).","journal-title":"Eur. J. Cancer"},{"key":"6366_CR22","doi-asserted-by":"publisher","first-page":"e1002201","DOI":"10.1371\/journal.pmed.1002201","volume":"13","author":"C Lefebvre","year":"2016","unstructured":"Lefebvre, C. et al. Mutational profile of metastatic breast cancers: A Retrospective Analysis. PLoS Med. 13, e1002201 (2016).","journal-title":"PLoS Med."},{"key":"6366_CR23","doi-asserted-by":"publisher","first-page":"4419","DOI":"10.1007\/s13277-013-1581-6","volume":"35","author":"R Zhang","year":"2014","unstructured":"Zhang, R. & Song, C. Loss of CSMD1 or 2 may contribute to the poor prognosis of colorectal cancer patients. Tumor Biol. 35, 4419\u20134423 (2014).","journal-title":"Tumor Biol."},{"key":"6366_CR24","doi-asserted-by":"publisher","first-page":"e58731","DOI":"10.1371\/journal.pone.0058731","volume":"8","author":"AY Shull","year":"2013","unstructured":"Shull, A. Y. et al. Somatic mutations, allele loss, and DNA methylation of the cub and sushi multiple domains 1 (CSMD1) gene reveals association with early age of diagnosis in colorectal cancer patients. PLoS ONE 8, e58731 (2013).","journal-title":"PLoS ONE"},{"key":"6366_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jpha.2016.09.003","volume":"7","author":"H Cui","year":"2017","unstructured":"Cui, H., Lan, X., Lu, S. M., Zhang, F. J. & Zhang, W. G. Bioinformatic prediction and functional characterization of human KIAA0100 gene. J. Pharm. Ana 7, 10\u201318 (2017).","journal-title":"J. Pharm. Ana"},{"key":"6366_CR26","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1093\/carcin\/bgs148","volume":"33","author":"P Liu","year":"2012","unstructured":"Liu, P. et al. Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis 33, 1270\u20131276 (2012).","journal-title":"Carcinogenesis"},{"key":"6366_CR27","doi-asserted-by":"publisher","first-page":"e1006081","DOI":"10.1371\/journal.pgen.1006081","volume":"12","author":"B Zhao","year":"2016","unstructured":"Zhao, B. & Pritchard, J. R. Inherited disease genetics improves the identification of cancer-associated genes. PLoS Genet. 12, e1006081 (2016).","journal-title":"PLoS Genet."},{"key":"6366_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14209","volume":"8","author":"T Schober","year":"2017","unstructured":"Schober, T. et al. A human immunodeficiency syndrome caused by mutations in CARMIL2. Nat. Commun. 8, 14209 (2017).","journal-title":"Nat. Commun."},{"key":"6366_CR29","doi-asserted-by":"publisher","unstructured":"Zhang, Y. et al. Whole-exome sequencing identifies novel somatic mutations in chinese breast cancer patients. J Mol Genet Med 9, https:\/\/doi.org\/10.4172\/1747-0862.1000183 (2015).","DOI":"10.4172\/1747-0862.1000183"},{"key":"6366_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-137","volume":"13","author":"Q Wang","year":"2013","unstructured":"Wang, Q., Ma, C. & Kemmner, W. Wdr66 is a novel marker for risk stratification and involved in epithelial-mesenchymal transition of esophageal squamous cell carcinoma. BMC Cancer 13, 137 (2013).","journal-title":"BMC Cancer"},{"key":"6366_CR31","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega, F. et al. Oncogenic signaling pathways in the cancer genome atlas. Cell 173, 321 (2018).","journal-title":"Cell"},{"key":"6366_CR32","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/nature09208","volume":"466","author":"ZY Kan","year":"2010","unstructured":"Kan, Z. Y. et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466, 869\u2013U103 (2010).","journal-title":"Nature"},{"key":"6366_CR33","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1158\/1078-0432.CCR-15-0964","volume":"22","author":"H Green","year":"2016","unstructured":"Green, H. et al. Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities. Clin. Cancer Res. 22, 366\u2013373 (2016).","journal-title":"Clin. Cancer Res."},{"key":"6366_CR34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/OLQ.0000000000000533","volume":"44","author":"BD Taylor","year":"2017","unstructured":"Taylor, B. D. et al. Whole-exome sequencing to identify novel biological pathways associated with infertility after pelvic inflammatory disease. Sex Transm. Dis. 44, 35\u201341 (2017).","journal-title":"Sex Transm. Dis."},{"key":"6366_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/joim.12565","volume":"281","author":"SN Cox","year":"2017","unstructured":"Cox, S. N. et al. Multiple rare genetic variants co-segregating with familial IgA nephropathy all act within a single immune-related network. J. Intern. Med. 281, 189\u2013205 (2017).","journal-title":"J. Intern. Med."},{"key":"6366_CR36","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/gim.2014.89","volume":"17","author":"C Esteban-Jurado","year":"2015","unstructured":"Esteban-Jurado, C. et al. Whole-exome sequencing identifies rare pathogenic variants in new predisposition genes for familial colorectal cancer. Genet. Med. 17, 131\u2013142 (2015).","journal-title":"Genet. Med."},{"key":"6366_CR37","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","volume":"29","author":"S Zheng","year":"2016","unstructured":"Zheng, S. et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell. 29, 723\u2013736 (2016).","journal-title":"Cancer Cell."},{"key":"6366_CR38","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/onc.2015.185","volume":"35","author":"KJ Kurppa","year":"2016","unstructured":"Kurppa, K. J., Denessiouk, K., Johnson, M. S. & Elenius, K. Activating ERBB4 mutations in non-small cell lung cancer. Oncogene 35, 1283\u20131291 (2016).","journal-title":"Oncogene"},{"key":"6366_CR39","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/978-1-62703-727-3_24","volume":"1102","author":"C Lau","year":"2014","unstructured":"Lau, C., Killian, K. J., Samuels, Y. & Rudloff, U. ERBB4 mutation analysis: emerging molecular target for melanoma treatment. Methods Mol. Biol. 1102, 461\u2013480 (2014).","journal-title":"Methods Mol. Biol."},{"key":"6366_CR40","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1038\/bjc.2014.412","volume":"111","author":"T Schenk","year":"2014","unstructured":"Schenk, T., Stengel, S. & Zelent, A. Unlocking the potential of retinoic acid in anticancer therapy. Br. J. Cancer 111, 2039\u20132045 (2014).","journal-title":"Br. J. Cancer"},{"key":"6366_CR41","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1093\/jnci\/89.9.602","volume":"89","author":"JD Minna","year":"1997","unstructured":"Minna, J. D. & Mangelsdorf, D. J. Retinoic acid receptor expression abnormalities in lung cancer: important clues or major obstacles? J. Natl. Cancer Inst. 89, 602\u2013604 (1997).","journal-title":"J. Natl. Cancer Inst."},{"key":"6366_CR42","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/jnci\/92.10.826","volume":"92","author":"M Widschwendter","year":"2000","unstructured":"Widschwendter, M. et al. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J. Natl. Cancer Inst. 92, 826\u2013832 (2000).","journal-title":"J. Natl. Cancer Inst."},{"key":"6366_CR43","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/nature09208","volume":"466","author":"Z Kan","year":"2010","unstructured":"Kan, Z. et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466, 869\u2013873 (2010).","journal-title":"Nature"},{"key":"6366_CR44","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nrc3521","volume":"13","author":"M O\u2019Hayre","year":"2013","unstructured":"O\u2019Hayre, M. et al. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat. Rev. Cancer 13, 412\u2013424 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"6366_CR45","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1093\/annonc\/mdr522","volume":"23","author":"NG Chau","year":"2012","unstructured":"Chau, N. G. et al. A phase II study of sunitinib in recurrent and\/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Ann. Oncol. 23, 1562\u20131570 (2012).","journal-title":"Ann. Oncol."},{"key":"6366_CR46","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/jjco\/hyn146","volume":"39","author":"JO Lee","year":"2009","unstructured":"Lee, J. O. et al. Metastatic adrenocortical carcinoma treated with sunitinib: a case report. Jpn. J. Clin. Oncol. 39, 183\u2013185 (2009).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"6366_CR47","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1210\/jc.2012-1419","volume":"97","author":"M Kroiss","year":"2012","unstructured":"Kroiss, M. et al. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J. Clin. Endocrinol. Metab. 97, 3495\u20133503 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"6366_CR48","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114\u20132120 (2014).","journal-title":"Bioinformatics"},{"key":"6366_CR49","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297\u20131303 (2010).","journal-title":"Genome Res."},{"key":"6366_CR50","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/0471250953.bi1110s43","volume":"43","author":"GA Van der Auwera","year":"2013","unstructured":"Van der Auwera, G. A. et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinforma. 43, 11\u201333 (2013). 11 10.","journal-title":"Curr. Protoc. Bioinforma."},{"key":"6366_CR51","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"6366_CR52","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1093\/bioinformatics\/btr329","volume":"27","author":"AB Olshen","year":"2011","unstructured":"Olshen, A. B. et al. Parent-specific copy number in paired tumor-normal studies using circular binary segmentation. Bioinformatics 27, 2038\u20132046 (2011).","journal-title":"Bioinformatics"},{"key":"6366_CR53","doi-asserted-by":"publisher","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","volume":"12","author":"E Talevich","year":"2016","unstructured":"Talevich, E., Shain, A. H., Botton, T. & Bastian, B. C. CNVkit: Genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput. Biol. 12, e1004873 (2016).","journal-title":"PLoS Comput. Biol."},{"key":"6366_CR54","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nbt.2203","volume":"30","author":"SL Carter","year":"2012","unstructured":"Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413\u2013421 (2012).","journal-title":"Nat. Biotechnol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-06366-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-06366-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-06366-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T15:55:43Z","timestamp":1693929343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-06366-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,9]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["6366"],"URL":"https:\/\/doi.org\/10.1038\/s41467-018-06366-z","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,9]]},"assertion":[{"value":"9 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4172"}}